Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 14, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 1,800,000 ordinary shares.
- Price per Share: 1,265.28 pence.
- Treasury Shares Held: 357,262,158 shares (representing 6.31% of total voting rights).
- Shares in Issue: 5,664,948,238 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,800,000 shares on August 14, 2007. These shares are intended to be held in Treasury. Consequently, the total number of shares in issue (excluding Treasury) is 5,664,948,238, which serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total number of shares in issue (5,664,948,238) for accurate calculation of ownership percentages under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (357,262,158) and its impact on total voting rights (6.31%).
- Note that this filing does not contain financial performance data; refer to Form 20-F or interim reports for revenue and profit metrics.